Life Bio Shares Early Trial Results for Glaucoma Treatment
Early Signals Point Toward a New Therapeutic Path
Life Biosciences, a biotech firm focused on cellular rejuvenation therapies, released interim Phase 1 data for ER-100 in patients with open-angle glaucoma. The study enrolled three participants who received a single intravitreal injection of ER-100 combined with daily oral doxycycline. Results showed the treatment was well-tolerated, with no serious adverse events reported during the observation period.
Health news
Vegan Diets May Reduce Gut Bacteria Diversity, Study Finds
Music with beats cuts stress hormone more than pink noise
Epigenetic Shifts Can Trigger Liver Cancer Without DNA Damage
Blood Clots and Brain Tumors Linked by Overactive PlateletsThe trial design targets the underlying cellular aging mechanisms that contribute to glaucoma progression. By using a rejuvenation-based approach, the company aims to restore functional capacity in affected eye tissue rather than merely managing symptoms. This marks the first-in-human testing of this specific formulation.
The interim data suggests that ER-100 may help slow or reverse damage to the optic nerve, a key feature of open-angle glaucoma. Researchers noted that participants maintained stable intraocular pressure throughout the study window. No participant required rescue medication or surgical intervention during the trial.
What Does This Mean for Glaucoma Patients?
The combination with doxycycline is intended to reduce inflammation and support tissue repair. This dual approach distinguishes the therapy from conventional glaucoma treatments, which primarily focus on lowering eye pressure. The company plans to expand the trial to a larger cohort to confirm efficacy and long-term safety.
For patients living with open-angle glaucoma, these early results offer a potential alternative to standard care. If the expanded trial confirms the Phase 1 findings, ER-100 could become a disease-modifying option rather than a symptomatic treatment. The biotech firm will present the full dataset at an upcoming ophthalmology conference.
Frequently Asked Questions
What is ER-100? ER-100 is an investigational cellular rejuvenation medicine developed by Life Biosciences. It is designed to target aging-related cellular decline in the eye.
How many people were in the Phase 1 trial? The interim data covers three participants with open-angle glaucoma. Each received one intravitreal injection of ER-100 plus daily oral doxycycline.
What were the main safety findings? No serious adverse events were reported. Participants tolerated the treatment well, with stable eye pressure maintained throughout the study period.